Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

STAT's podcast The Readout LOUD this week discusses cannabinoid receptor drugs in weight loss, what the Fed's rates cut might ...

Hi there, this is Ailbhe Rea, a Bloomberg UK Associate editor based in Westminster. Rachel Reeves, if you’re reading, look ...

Vaxcyte's stock surges on promising vaccine data, offering potential upside despite competition. Learn more on PCVX here.

Wilde, a Bloomberg UK journalist and editor on the Readout. Hope you enjoy today’s newsletter. Well, what a pivot week this ...

Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

Viking Therapeutics (VKTX) stock rises as J.P. Morgan gives a buy-equivalent rating on upcoming Phase 1 trial results for ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.

Keysight Technologies, Inc. (NYSE: KEYS) introduces Quantum Circuit Simulation (Quantum Ckt Sim), an innovative circuit design environment that speeds ...